New guidelines on primary PCI for patients with STEMI: changing insights by E.E. van der Wall
Editor’s CommEnt
Published online: 8 December 2015
© The Author(s) 2015. This article is published with open access at Springerlink.com
New guidelines on primary PCI for patients with STEMI: 
changing insights
E.E. van der Wall
Neth Heart J (2016) 24:93–95
DOI 10.1007/s12471-015-0780-8
five levels of evidence were used: Level A, B-R (ran-
domised), B-NR (non-randomised), C-LD (limited data), 
and Level C-EO (expert opinion).
The scope of the 2015 focused update was restricted to 
two main areas: 1) multi-vessel PCI, and 2) thrombus aspi-
ration in patients with STEMI undergoing primary PCI.
1) Culprit artery-only PCI versus multi-vessel PCI
The 2013 recommendation was Class III (Harm), indicating 
that PCI should not be performed in a non-infarct artery at 
the time of primary PCI in patients with STEMI who are 
haemodynamically stable (Level of Evidence B).
The new recommendation of 2015 is now Class IIb, 
demonstrating that PCI of a non-infarct artery may be con-
sidered in selected patients with STEMI and multi-vessel 
disease who are haemodynamically stable, either at the time 
of primary PCI or as a planned staged procedure (Level of 
Evidence B-R). It was commented that the 2015 recom-
mendation changed from Class III (Harm) to Class IIb and 
expanded the time frame in which multi-vessel PCI could 
be performed.
2) Aspiration thrombectomy
Recommendations of 2011/2013 were Class IIa, indicat-
ing that manual aspiration thrombectomy is reasonable for 
patients undergoing primary PCI (Level of Evidence B).
The new recommendation of 2015 is Class IIb, show-
ing that the usefulness of selective and bailout aspiration 
thrombectomy in patients undergoing primary PCI is not 
well established (Level of Evidence C-LD). The recom-
mendation of 2015 for routine aspiration thrombectomy is 
now Class III (No benefit), indicating that routine aspiration 
thrombectomy before primary PCI is not useful (Level of 
Evidence A).
Recently, the American College of Cardiology, American 
Heart Association, and Society for Cardiovascular Angiog-
raphy and Interventions (ACC/AHA/SCAI) have updated 
their guidelines on primary percutaneous coronary inter-
vention (PCI) for patients with ST-segment-elevation myo-
cardial infarction (STEMI). These organisations have made 
several remarkable changes from previous recommenda-
tions. The new guidelines were published in the Journal of 
the American College of Cardiology in October 2015 [1].
The background for the 2015 focused update was novel 
findings from clinical trials presented at the major cardiol-
ogy congresses from 2013 to 2015 and new information 
from other peer-reviewed studies published up to August 
2015. These recent studies were thoroughly reviewed by the 
2011 PCI and 2013 STEMI Guideline Writing Committees 
and the Task Force to identify trials and other crucial data 
that might affect guideline recommendations. This informa-
tion was considered important enough to prompt updated 
recommendations and was included in evidence tables in 




The Classes of Recommendation and Levels of Evi-
dence were derived independently of one another according 
to established criteria. Five different classes were distin-
guished: Class I (Strong), IIa (Moderate), IIb (Weak), III 
(No benefit, moderate), and Class III (Harm, strong). Also, 
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It was commented that the 2015 recommendation 
changed from Class IIa to Class IIb for selective and bailout 
aspiration thrombectomy before PCI and that routine aspira-
tion thrombectomy before primary PCI is not useful.
In summary, the 2015 report has significantly updated 
the 2011 ACC/AHA/SCAI Guideline for PCI and the 2013 
ACC/AHA Guideline for the Management of STEMI. The 
2015 focused update did address two major issues: 1) the 
setting of primary PCI for multi-vessel PCI, and 2) the use-
fulness of thrombus aspiration. Regarding multi-vessel PCI, 
new evidence from recent clinical trials clearly showed that 
treating other non-culprit stenosed coronary arteries may 
be safe and beneficial in selected patients with multi-vessel 
disease. The 2015 focused update states that treating the 
non-culprit stenosed arteries with a stent may be considered 
in patients with STEMI who are haemodynamically stable 
at the time of the primary PCI. Concerning the usefulness of 
thrombus aspiration, the prior Class IIa recommendation for 
aspiration thrombectomy was changed to Class IIb in 2015. 
There are at present insufficient data to assess the poten-
tial benefit of a strategy of selective or bailout aspiration 
thrombectomy. The 2015 focused update states that routine 
aspiration thrombectomy before primary PCI is currently 
not recommended.
The above-mentioned new recommendations may also 
have consequences for newly planned guidelines of the 
European Society of Cardiology (ESC) on STEMI. In 2012 
the ESC STEMI guidelines reported: 1) that primary PCI 
should be limited to the culprit vessel with the exception 
of cardiogenic shock and persistent ischaemia after PCI of 
the supposed culprit lesion (Class IIa, Level B), and 2) that 
routine thrombus aspiration should be considered (Class 
IIa, Level B) [2]. The updated ESC STEMI guidelines are 
among the new publications scheduled in 2017.
What can be learned from new recommendations and 
guidelines? Generally speaking, according to the defini-
tion of the ESC, guidelines aim to present all the relevant 
evidence on a particular clinical issue in order to help 
physicians to weigh the benefits and risks of a particular 
diagnostic or therapeutic procedure [3–6]. They should 
be helpful in everyday clinical medical decision-making. 
More importantly, guidelines should be updated every 4 to 
5 years in order to offer the patient the best possible treat-
ment based on the most actual findings [7–11]. An updated 
guideline, however, does not necessarily invalidate the pre-
vious guideline; a new guideline predominantly reflects the 
progress in science and its ensuing change of views over 
time. New guidelines are built on older guidelines based on 
moving insights inspired by advanced research [12–14]. In 
itself, each guideline represents the level of science at that 
particular point in time. Fortunately, progress in research 
teaches us that the level of science moves forward implying 
that guidelines have to be regularly revisited, primarily in 
the interest of optimal diagnosis and treatment of the patient 
[15–18]. In this respect, the 2015 focused update on primary 
PCI for patients with STEMI offers an illustrative example 
of changing insights based on novel findings [1].
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